Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells

Blood

Volumn 90, Issue 2, 1997, Pages 549-561

  Cardoso, Angelo A ^a   Seamon, Mark J ^b   Afonso, Hernani M ^b   Ghia, Paolo ^b   Boussiotis, Vassiliki A ^b   Freeman, Gordon J ^b   Gribben, John G ^b   Sallan, Stephen E ^b   Nadler, Lee M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BONE MARROW; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

EID: 0030792868     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.2.549     Document Type: Article

References (34)

1. Schwartz RH, Mueller DL, Jenkins MK, Quill H: T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 54:605, 1989
2. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721, 1991
3. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2, a CTLA4 counter-receptor that costimulates human T cell proliferation. Science 262:909, 1993
4. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The critical role of CD28 signaling in the prevention of human T-cell anergy. Res Immunol 146:140, 1995
5. Ostrand-Rosenberg S: Tumor immunotherapy: The tumor cell as antigen-presenting cell. Curr Opin Immunol 6:722, 1994
6. Dranoff G, Mulligan RC: Gene transfer as cancer therapy. Adv Immunol 58:417, 19
7. Schultze JS, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200, 1995
8. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88:41, 1996
9. Livingston PO, Shiku H, Bean MA, Pinsky CM, Oettgen HF, Old LJ: Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int J Cancer 24:34, 1979
10. Mukherji B, MacAlister TJ: Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med 158:240, 1983
11. Knuth A, Danowski B, Oettgen HF, Old LJ: T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci USA 81:3511, 1984
12. Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ: Cellular immune response to human sarcomas: Cytotoxic T cell clones reactive with autologous sarcomas. J Immunol 137:3042, 1986
13. Yasumura S, Hirabayashi H, Schwartz DR, Toso JF, Johnson JT, Herberman RB, Whiteside TL: Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res 53:1461, 1993
14. Kannagi M, Sugamura K, Sato H, Okochi K, Uchino H, Hinuma Y: Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells. J Immunol 130:2942, 1983
15. Mitsuya H, Matis LA, Megson M, Bunn PA, Murray C, Mann DL, Gallo RC, Broder S: Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med 158:994, 1983
16. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG: Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: Implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci USA 89:5862, 1992
17. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157, 1992
18. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulins idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
19. Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP: Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146:1700, 1991
20. - T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC). Int J Cancer 51:962, 1992
21. Faber LM, van Luxemburg-Heijs AP, Willemze R, Falkenburg JHF: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283, 1992
22. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM: B7 provides a costimulatory signal which induces stimulated T cells to proliferate and secrete interleukin-2. Proc Natl Acad Sci USA 88:6575, 1991
23. Freeman GF, Boussiotis VA, Anumanthan A, Bernstein GM, Ke X-Y, Rennert PD, Gray GS, Gribben JG, Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523, 1995
24. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F: Soluble CD40-ligand can replace the normal T cell derived CD40-ligand signal to B cells in T-dependent activation. J Exp Med 177:1209, 1993
25. 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181, 1968
26. Liu Y, Janeway CA Jr: Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 89:3845, 1992
27. Baskar S, Nabavi N, Glimcher L, Ostrand-Rosenberg S: Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother 14:209, 1993
28. Boussiotis V, Freeman GJ, Gray G, Gribben JG, Nadler LM: B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of alloantigen-specific tolerance. J Exp Med 178:1753, 1993
29. Nabholz M, Engers HD, Collavo D, North M: Cloned T-cell lines with specific cytolytic activity. Curr Top Microbiol Immunol 81:176, 1978
30. Glasebrook AL, Fitch FW: T-cell lines which cooperate in generation of specific cytolytic activity. Nature 278:171, 1979
31. Glasebrook AL, Fitch FW: Alloreactive cloned T cell lines. I. Interactions between cloned amplifier and cytolytic T cell lines. J Exp Med 151:876, 1980
32. von Boehmer H, Haas W: Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen. J Exp Med 150:1134, 1979
33. Nishioka WK, Welsh RM: Susceptibility to cytotoxic T lymphocyte-induced apoptosis a function of the proliferative status of the target. J Exp Med 179:769, 1994
34. + cytotoxic T cells. Proc Natl Acad Sci USA 91:4185, 1994